1-3 of 3
Daijing Yuan
Close
Sort by
Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Daijing Yuan, Hongxia Zhao, Jun Xiao, Wei Wang, Huamao Wang, Zonghai LI
Journal: Blood
Blood (2022) 140 (Supplement 1): 4564–4565.
https://doi.org/10.1182/blood-2022-168610
Published: 2022
Journal Articles

Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma

Siguo Hao, MD PhD, Jie Jin, MD PhD, Songfu Jiang, MD, Zonghai Li, MD PhD, Wenhao Zhang, MD PhD, Min Yang, MD PhD, Kang Yu, MD, Wei Wang, MDPhD, Linjun Chen, MD PhD, Haitao Meng, MD PhD, Mingxia He, MD, Jun Xiao, MD, Rong Tao, MD PhD, Xin Huang, MD PhD, Chongyun Xing, MD, Daijing Yuan, MD, Jianbo Wan, MD PhD, Shasha Wang, MD PhD, Lihui Dai, BS, Hong Ma, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140156
Published: 2020
Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Jin Jie, MD PhD, Siguo Hao, MD PhD, Songfu Jiang, MD, Zonghai Li, MD PhD, Min Yang, MD PhD, Wenhao Zhang, MD PhD, Kang Yu, MD, Jun Xiao, MD, Haitao Meng, MD PhD, Liyuan Ma, MD PhD, Mingxia He, MD, Wei WANG, MD PhD, Xin Huang, MD PhD, Linjun Chen, MD PhD, Chongyun Xing, MD, Daijing Yuan, MD, Shasha Wang, MD PhD, Rong Tao, MD PhD, Lihui Dai, BS, Hong Ma, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4435.
https://doi.org/10.1182/blood-2019-126104
Published: 2019